Tech Company Financing Transactions
AdvanCell Funding Round
AdvanCell closed a $18 million Series B funding round on 8/24/2022. Backers included Morningside Group.
Transaction Overview
Company Name
Announced On
8/24/2022
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Series B
Investors
Morningside Group (Lead Investor) (Anthony Aiudi)
Proceeds Purpose
The company intends to use the funds to accelerate growth and advance lead clinical program 212Pb-ADVC001, a treatment for metastatic prostate cancer, expand manufacturing platform footprint and progress internal and partnership programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Level 7, Macquarie House, 167 Macquarie St,
Sydney, NSW, 2000
AU
Sydney, NSW, 2000
AU
Phone
Undisclosed
Website
Email Address
Overview
AdvanCell is a radiopharmaceutical company developing next-generation cancer treatments. AdvanCell's targeted alpha therapies are powered by a platform technology -- a world-first alpha isotope generator which addresses the greatest unmet need in targeted alpha therapy -- the reliable and scalable supply of isotope.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Bill Ferris
Chief Executive Officer
Andrew Adamovich
Chief Technical Officer
Simon Puttick
Browse more venture capital transactions:
Prev: 8/24/2022: Lunar Energy venture capital transaction
Next: 8/24/2022: Scalenut venture capital transaction
Share this article
Where The Data Comes From
We record tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs